|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author, Year  Study Design | Were eligibility criteria clearly described? | Were subjects representative of the overall source population? | Did the study apply inclusion/ exclusion criteria uniformly  to all comparison groups of the study? | Did the study avoid inappropriate exclusions? | Is the selection of the comparison group appropriate, after taking  into account feasibility and ethical considerations? | Did the study guard against risk of survivor bias? | Were groups similar at baseline? | Were outcome assessors masked to the exposure status of participants? | What was the overall attrition? | What was the differential attrition? | Did the study have high attrition raising concern for bias? |
| Polesky 1996156  Retrospective cohort  87 | Yes | NR (no data provided on the source population) | Yes | Yes | Yes | Yes | Yes, as reported, but baseline data not available for all subjects (e.g., limited data available on HIV status, IV drug use) | No | 14% | 27 patients reported lost to followup immediately after skin test conversions in the no-therapy group (38%); 0 (0) in other groups | Not overall, but high differential attrition when compared with the no-therapy group |

**Abbreviations:** HIV=human immunodeficiency virus; IV=intravenous; NR=not reported.